BRL-501 / BRL Medicine - LARVOL DELTA

The safety and efficacy evaluation of enhanced autologous PSMA chimeric antigen receptor T cells in the treatment of refractory castration resistant prostate cancer (ESMO 2025) - P1 | "Here, we have designed an enhanced autologous CAR-T therapy (BRL-501), which targets prostate cancer-specific membrane antigens (PSMA)and is designed to secrete cytokines, thereby activating the immune system and enhancing the overall anti-tumor response...Shancheng Ren. Funding National Natural Science Foundation of China(82125025) Shanghai Shenkang Hospital Development Center (SHDC2022CRT005)."

CAR T-Cell Therapy • Clinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor